Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-22
2009-02-17
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S500000
Reexamination Certificate
active
07491717
ABSTRACT:
The present invention relates to the CGRP antagonists of general formulawherein A, X, D, E, G, M, Q and R1to R3are defined as in claim1,the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.
REFERENCES:
patent: 5442044 (1995-08-01), Hoover et al.
patent: 6344449 (2002-02-01), Rudolf et al.
patent: 6521609 (2003-02-01), Doods et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 2004/0132716 (2004-07-01), Rudolf et al.
patent: 2004/0192729 (2004-09-01), Rudolf et al.
patent: 2005/0234067 (2005-10-01), Mueller et al.
patent: 2005/0282857 (2005-12-01), Rudolf et al.
patent: 2006/0079504 (2006-04-01), Rudolf et al.
patent: 2006/0252931 (2006-11-01), Mueller
patent: 2007/0049581 (2007-03-01), Mueller
patent: 2007/0072847 (2007-03-01), Mueller
patent: 2008/0086003 (2008-04-01), Ries et al.
patent: 2378428 (2000-08-01), None
patent: 2361939 (2000-09-01), None
patent: 2503455 (2004-05-01), None
patent: 2503462 (2004-05-01), None
patent: 0438233 (1991-07-01), None
patent: WO0018764 (2000-04-01), None
patent: WO03104236 (2003-12-01), None
patent: WO2004037810 (2004-05-01), None
patent: WO2004037811 (2004-05-01), None
Mallee, J. J., et al; Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists; The Journal of Biological Chemistry (Apr. 19, 2002) vol. 277, No. 16, pp. 14294-14928; The American Society for Biochemistry and Molecular Biology, Inc.
Doods, et al; Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist; British Journal of Pharmacology (2000) vol. 129; pp. 420-423; Macmillan Publishers Ltd.
Halliwell; Cationic Amphiphilic Drug-Induced Phospholipidosis; Toxicologic Pathology; 1997; vol. 25; No. 1; pp. 1-8.
Arndt Kirsten
Doods Henri
Dreyer Alexander
Lustenberger Philipp
Mueller Stephan Georg
Boehringer Ingelheim International GmbH
Devlin Mary-Ellen M.
Kifle Bruck
Morris Michael P.
Stempel Alan R.
LandOfFree
Selected CGRP-antagonists, process for preparing them and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selected CGRP-antagonists, process for preparing them and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selected CGRP-antagonists, process for preparing them and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068907